Moderna's full pipeline may fuel long-term growth.

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...

New research shows promising signs that the Pfizer and Moderna vaccines might offer protection for a longer time than previously thought. And that protection could potentially last for years Health ...

Feb 27 (Reuters) - Europe's medicines regulator recommended approval for Moderna's COVID and flu combination vaccine on Friday, putting it on track to become the ‌first single shot to protect people ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk melanoma, while the FDA granted expedited review and an August 5, 2026 ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...

Questions about the COVID-19 shot abound as federal recommendations shift and medical groups issue clashing guidance.

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...